Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 3/20 | 0.41 |
| ▸ | IKBKB | O14920 | 9/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | METAP1 | P53582 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CISD2 | Q8N5K1 | 1/20 | 0.36 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6192110 | 0.95 | LCK (0.38) | LCKIKBKBCA1CA2RXFP1 | |
| SCHEMBL3607693 | 0.87 | LCK (0.42) | LCKCA1CA2RXFP1METAP1 | |
| SCHEMBL101455 | 0.86 | RAF1 (0.42) | LCK | |
| SCHEMBL28448428 | 0.83 | CTSS (0.44) | CA2AAK1 | |
| SCHEMBL22774869 | 0.82 | LCK (0.41) | LCKCA1CA2RXFP1METAP1 | |
| SCHEMBL22774665 | 0.81 | LCK (0.43) | LCKCA1CA2RXFP1METAP1 | |
| SCHEMBL28449337 | 0.81 | IKBKB (0.38) | IKBKBRXFP1 | |
| SCHEMBL1681287 | 0.80 | IKBKB (0.39) | LCKIKBKBCA1CA2NPC1 | |
| SCHEMBL22774510 | 0.79 | LCK (0.40) | LCKCA1CA2RXFP1METAP1 | |
| SCHEMBL490588 | 0.78 | IKBKB (0.57) | IKBKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022134147-A1 | COMPOUND AND METHOD FOR PREPARING SUBSTITUTED [5,6]CYCLIC-4(3H)-PYRIMIDONE COMPOUND FROM SAME | 南京正济医药研究有限公司 | 2022-06-30 | — | — | WO | disclosed |
| US-20100029754-A1 | THIOPHENE-CARBOXAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF THE ENZYME IKK-2 | ASTRAZENECA AB (SW) | 2010-02-04 | — | — | US | disclosed |
| US-20090215829-A1 | THIOPHENE CARBOXAMIDES AS INHIBITORS OF THE ENZYME IKK-2 | MORLEY ANDREW DAVID | 2009-08-27 | — | — | US | disclosed |
| US-7572826-B2 | Thiophene-carboxamide derivatives and their use as inhibitors of the enzyme IKK-2 | ASTRAZENECA AB (SE) | 2009-08-11 | — | — | US | disclosed |
| US-7553868-B2 | Thiophene carboxamides as inhibitors of the enzyme IKK-2 | ASTRAZENECA AB (SE) | 2009-06-30 | — | — | US | disclosed |
| EP-1583756-B9 | THIOPHENE CARBOXAMIDES AS INHIBITORS OF THE ENZYME IKK-2 | ASTRAZENECA AB (SE) | 2008-01-09 | — | — | EP | disclosed |
| EP-1583756-B1 | THIOPHENE CARBOXAMIDES AS INHIBITORS OF THE ENZYME IKK-2 | ASTRAZENECA AB (SE) | 2007-10-03 | — | — | EP | disclosed |
| EP-1421079-B1 | THIOPHENYL COMPOUNDS AS MEDICAMENTS | ASTRAZENECA AB (SE) | 2007-02-07 | — | — | EP | disclosed |
| US-7098240-B2 | Compounds | ASTRAZENECA AB (SE) | 2006-08-29 | — | — | US | disclosed |
| US-20060111431-A1 | Thiophene carboxanmides as inhibitors of the enzyme ikk-2 | ASTRAZENECA AB (SE) | 2006-05-25 | — | — | US | disclosed |
| US-20060058522-A1 | Thiophene-carboxamide derivatives and their use as inhibitors of the enzyme ikk-2 | ASTRAZENECA AB (SE) | 2006-03-16 | — | — | US | disclosed |
| EP-1583756-A1 | THIOPHENE CARBOXAMIDES AS INHIBITORS OF THE ENZYME IKK-2 | AstraZeneca AB (SE) | 2005-10-12 | — | — | EP | disclosed |
| US-20040235821-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2004-11-25 | — | — | US | disclosed |
| WO-2004063185-A1 | THIOPHENE CARBOXAMIDES AS INHIBITORS OF THE ENZYME IKK-2 | ASTRAZENECA AB (SE) | 2004-07-29 | — | — | WO | disclosed |
| EP-1421079-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2004-05-26 | — | — | EP | disclosed |
| WO-2003010163-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2003-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215829-A1 | THIOPHENE CARBOXAMIDES AS INHIBITORS OF THE ENZYME IKK-2 | RELA, NFKBIA, CSNK1E | LCK 372/4885IKBKB 7/4885CA1 4101/4885 |
| US-20060058522-A1 | Thiophene-carboxamide derivatives and their use as inhibitors of the enzyme ikk-2 | NFKBIA, RELA, IKBKE | LCK 226/4885IKBKB 5/4885CA1 4032/4885 |
| US-20060111431-A1 | Thiophene carboxanmides as inhibitors of the enzyme ikk-2 | RELA, NFKBIA, CHUK | LCK 373/4885IKBKB 5/4885CA1 3968/4885 |
| US-20100029754-A1 | THIOPHENE-CARBOXAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF THE ENZYME IKK-2 | NFKBIA, RELA, IKBKE | LCK 226/4885IKBKB 5/4885CA1 4032/4885 |
| US-20040235821-A1 | Novel compounds | ABCG2, UGT1A1, SULT1E1 | LCK 2825/4885IKBKB 2823/4885CA1 2842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.